Please ensure Javascript is enabled for purposes of website accessibility

Why Celator Pharmaceuticals Shares Soared 30.7% Higher in April

By Todd Campbell - May 4, 2016 at 9:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares surged after the company reported additional efficacy data for its lead drug, Vyxeos.

IMAGE SOURCE: FLICKR USER STOCKMONKEYS.COM.

What: After surprising investors in March with solid efficacy and safety results from a late-stage trial, shares of Celator Pharmaceuticals (NASDAQ: CPXX) continued to gain ground in April, increasing by 30.7% according to S&P Global Market Intelligence.

So what: Previously, Celator Pharmaceuticals reported phase 3 results for its Vyxeos showing that it delivers potentially best-in-class efficacy and safety in acute myeloid leukemia (AML) patients. Specifically, the overall survival of secondary AML patients taking Vyxeos was 9.56 months compared to 5.95 months for patients receiving the standard 7+3 chemotherapy regimen. Safety results were for Vyxeos were similar to the 7+3 cocktail. 

What makes that finding intriguing is that Vyxeos is an optimized formulation of cytarabine and daunorubicin, the two drugs that comprise the 7+3 treatment. Since Vyxeos is a reformulation of these two drugs and these drugs are already standard of care, the findings suggest doctors may be willing to switch over to it if it wins Food and Drug Administration approval.

That thinking was bolstered in April when Celator Pharmaceuticals reported more data showing that Vyxeos could help patients with AML cells that harbor the FLT3-ITD+ mutation. Typically, the FLT3-ITD+ mutation has been incredibly tough to treat, yet in this study, AML cells exhibiting FLT3-ITD were roughly five times more sensitive to Vyxeos than cells were with normal FLT3. That's important because roughly 24% of AML patients exhibit a FLT3 mutation, and as many as a third of those patients exhibit the FLT3-ITD mutation.  

Now what: In March, Celator Pharmaceuticals raised $40.6 million via an oversubscribed stock offering and that money will come in handy as management invests in sales and marketing ahead of a potential Vyxeos launch.

Management is targeting an FDA filing for Vyxeos approval in the third quarter and if approved, Vyxeos could begin shipping sometime next year. 

Given the long-term survival rate in secondary AML is around 10%, and this drug could significantly improve outcomes, there's a very good chance this drug will become the standard of care. According to the National Cancer Institute, there are roughly 20,000 new cases of AML diagnosed in the U.S. every year; and roughly a quarter of those patients are diagnosed with secondary AML.

Overall, Celator Pharmaceuticals has a chance to win away a big chunk of what industry watcher's peg as a $900 million-per-year market. That has me thinking that its current valuation is still attractive. Therefore, risk-tolerant investors who are able to withstand the risk of an FDA rejection may want to consider owning this stock in their portfolios.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.